Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets
Commercial success with Jakafi allows parallel development of many new cancer drug mechanisms beyond the IDO1 inhibitor epacadostat, which is on a fast track.
You may also be interested in...
Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.
Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.